The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Gastrointestinal stromal tumors of the esophagus in adults: a systematic review
Journal: Russian Journal of Evidence-Based Gastroenterology. 2025;14(1): 5‑28
Views: 621
Downloaded: 57
To cite this article:
Koshmanova AN, Yorgova DI, Vergus ES, Zharova ME, Nikonov EL. Gastrointestinal stromal tumors of the esophagus in adults: a systematic review. Russian Journal of Evidence-Based Gastroenterology.
2025;14(1):5‑28. (In Russ.)
https://doi.org/10.17116/dokgastro2025140115
Esophageal gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors of the gastrointestinal tract. Despite the increasing number of reported cases, systematic knowledge on this condition remains limited.
To summarize and organize data on the epidemiology, clinical presentation, diagnosis, and treatment of esophageal GISTs.
A systematic literature search was conducted in PubMed, Web of Science, Google Scholar, Cochrane Library, eLibrary, and CyberLeninka, covering publications from 1988 to 2024. Additional articles were identified through reference lists and manual searches.
A total of 1.113 articles were screened, and 59 studies (1.481 patients) were analyzed. The key findings were: esophageal GISTs predominantly affect men, with a mean age of 65 years. The condition is often diagnosed incidentally or after symptoms such as dysphagia, chest discomfort, weight loss, and bleeding. Tumors are most commonly located in the lower third of the esophagus (64%), with an average size of 6 cm. Surgical treatment was performed in 67.2% of cases, including esophagectomy (65.8%), enucleation (24.8%), esophagogastrectomy (5.7%), and subtotal esophageal resection (3.6%). Medical therapy was administered in 33.8% of cases, with neoadjuvant treatment in 44.4% and adjuvant therapy in 51.6%. The 5-year overall survival (OS) rate was 67.4%, with a median OS of 131 months. At a median follow-up of 24 months, 88% of patients remained progression-free, 8% experienced disease progression, and 4% died from the disease.
This systematic review provides a comprehensive analysis of the epidemiology, etiology, pathogenesis, clinical features, diagnosis, and treatment of esophageal GISTs. Most patients presented with tumor-related symptoms. Surgery, particularly esophagectomy and enucleation, remains the primary treatment approach, while tyrosine kinase inhibitors play a central role in medical therapy.
Keywords:
Authors:
Received:
02.10.2024
Accepted:
09.12.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.